September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
Your daily dose of the clinical news you may have missed.
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
August 27th 2024
The Omnipod 5 is now the first automated insulin delivery system available for both T1D and T2D in the US.
August 16th 2024
Primary care clinicians can screen at-risk individuals for type 1 diabetes with a single autoantibody panel. It pays to test and educate early, according to this author.
FDA Approves First Oral GLP-1 Receptor Agonist for T2D
Oral semaglutide, the first oral GLP-1 receptor agonsist, was approved by the FDA on Sept 20, 2019, becoming the only noninjectable formulation in the class.
Health of US Diabetes Patients Largely Unchanged since 2005
US adults with type 2 diabetes have acheived negligible change in blood glucose levels, blood pressure, LDL-C levels, and smoking status in the past 15 years, according to a new study.
PCPs are Missing Prediabetes, Survey Finds
Less than half of PCPs responding to a recent survey chose correct values for prediabetes screening tests and seemed unaware of other evidence-based recommendations for prediabetes.
US Diabetes Treatment is Missing the Mark
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
Diabetes and the Flu: A Dangerous Duo
Help keep patients with diabetes healthy this flu season with a few of these quick reminders on vaccination, medication, comorbidities, and more.
Diabetes Drug Costs Force Patients to Cut Corners
About 25% of patients with diabetes report asking a physician for a cheaper drug. Skipping doses and pill splitting are tactics used to cut costs.
New Approaches Improve Diagnosis, Prediction of Type 2 Diabetes
One US researcher notes that using A1c alone to classify diabetes may misdiagnose >33 million Americans. What are the other options and how well do they work? Read on.
Needle-free Hypoglycemia Treatment Approved
The novel intranasal glucagon delivered with a portable, single-use device could simplify treatment of this dangerous side effect of antidiabetes medications.
First Oral GLP-1 Agonist Showcased while Approval Pending
ADA 2019 ICYMI: Safety and efficacy of oral semaglutide in patients with T2DM was demonstrated in results of 3 PIONEER program clinical trials. Highlights, here.
Linagliptin Found Safe in T2DM Patients at High Cardiorenal Risk
ADA 2019--Linagliptin, the DPP-4 inhibitor, showed similar risk for first or recurrent CV events or hopspitalization vs placebo in T2DM patients with high cardiorenal risk in CARMELINA subanalysis.
SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes
ADA 2019-Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.
The Next Top 5 FDA-Cleared Apps for Primary Care
A personal EKG monitor, an app that wirelessly connects to a smart thermometer, and 3 more FDA-cleared apps for primary care.
4 FDA-Approved Continuous Glucose Monitoring Systems: An Update
Refresh your memory of 4 CGM systems that received FDA-approval in 2018. Each one offers innovative features to help enhance diabetes care.
Type 2 Diabetes: After the Diagnosis, Resist Inertia
Diabetes is a progressive disease and takes advantage of inaction. How would you manage our patient Mrs Davis?
Type 2 Diabetes: Clinical Suspicion and Diagnosis
Who is at risk for T2DM? How often should you screen? What are the cut offs for Dx? Revisit the basics in 5 minutes or less.
Medical Sequelae Impact QoL Among Individuals in Recovery
More than one-third of those in recovery from drug/alcohol use have chronic physical disease. A novel study looks at prevalence of health issues by type of substance used.
Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials
Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.
3 New Diabetes Studies, in Brief
Findings: a heart-healthy lifestyle reduces DM risk; 1 egg a day may protect against T2DM; and a new genetic risk score may improve DM diagnosis.
5 Top Diabetes Apps for Patients and their PCPs
Help your patients with diabetes help themselves. See 5 apps at-a-glance you can discuss at the next visit.
The Face of Undiagnosed Diabetes: True or False?
Sample: True or false? The prevalence of undiagnosed diabetes is higher among obese adults vs overweight adults.
Feet, Don’t Fail Me Now! Averting a Complication of Diabetes
Up to 50% of patients with diabetes may have signficant neuropathy, yet be asymptomatic. Here's how to avoid or attenuate the condition.
Diabetes and Dollars: Cost-of-Care Quiz
True or False: In 2015, Americans spent more on insulin glargine than any other drug. The answer and 9 more questions in our quiz.
Diabetes and Mentall Illness: 3 New Studies
Results include: The metabolic dangers of neuroleptic Rx in youth; prevalence of T2DM in minorities with severe mental illness; and gaps in care for mentally ill with T2DM.
Paradigms Shift in Type 2 Diabetes Management
Anything less than comprehensive care for type 2 diabetes is quickly becoming old school.
Keep Pushing On!
What to do when patients face their own "clinical inertia"? Here, 3 simple ways to help them push through.
Reducing Risk and Rates of Severe Hypoglycemia
Severe hypoglycemia is more prevalent than previously believed and also significantly underreported. Details from 3 studies at ADA 2018.
Novel Markers, Glycemic Variability Predict CV Events in Diabetes
From ADA 2018: Two new biomarkers predict CV events independently of conventional risk factors, plus post-hoc analysis of VADT.
Insulin Discontinuation and Other Measures of GLP-1 RA Efficacy
What is the impact on insulin dose, A1c, body weight of adding GLP-1 RA to a MDI insulin regimen? Three studies from ADA 2018 illuminate.
ADA 2018: CV Benefits of SGLT-2 Inhibitors
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
ADA 2018: Oral Agents and Insulin - Combined, Compared
Should you: Stop a DPP-4i when you start insulin? Prescribe initial triple combination Rx? What about SGLT2i + DPP-4i + MET vs insulin + MET? Find out.